Resources Repository
-
GuidelinesPublication 2012Modeling Good Research Practices - Overview: A Report of the ISPOR-SMDM Modeling Task Force-1
This paper provides an overview of the work of the joint Task Force between the …
This paper provides an overview of the work of the joint Task Force between the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) and the Society for Medical Decision Making (SMDM), provides the overarching recommendations, and discusses future work that is needed. The audience for these papers includes anyone who build models, stakeholders who utilize their results, and those concerned with the use of models to support decision making. This article is part 1 of…
Calibration/Validation | Costing Methods | Health Outcomes | Value of Information | Mathematical Models | State-Transition | Dynamic Transmission | Microsimulation | Dynamic Simulation | Decision Analysis | Infectious Diseases | Health/Medicine -
GuidelinesPublication 2012Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Task Force-7
This paper discusses how to improve trust in the use of health care models through …
This paper discusses how to improve trust in the use of health care models through validation and transparency. Validation involves face validity (wherein experts evaluate model structure, data sources, assumptions, and results), verification or internal validity (check accuracy of coding), cross validity (comparison of results with other models analyzing same problem), external validity (comparing model results to real-world results), and predictive validity (comparing model results with prospectively observed events). Recommendations are provided for nontechnical description…
Calibration/Validation | Costing Methods | Health Outcomes | Mathematical Models | Health/Medicine -
ToolInteractive 2020COVID-19 Antibody Tests: Calculator for Interpreting Test Results
Antibody testing can determine previous exposure to SARS-CoV-2 virus. This interactive calculator, linked to the article …
Antibody testing can determine previous exposure to SARS-CoV-2 virus. This interactive calculator, linked to the article below* on antibody testing for SARS-CoV-2 virus, allows users to vary the prior probability of infection, the sensitivity of SARS-CoV-2 antibody testing, and the specificity of SARS-CoV-2 antibody testing. Key points made in the article accompanying the interactive include: (1) antibody testing is likely to be most useful 2 weeks after infection, (2) sensitivity and specificity will vary over time and…
Test Performance | Technology Assessment | Probability/Bayes | Infectious Diseases | Clinical Care | Health/Medicine | Science/Technology -
GuidelinesWeb Portal 2017iDSI Reference Case for Economic Evaluation
This is a reference case which gives 12 principles to guide the planning, conduct and …
This is a reference case which gives 12 principles to guide the planning, conduct and reporting of health economic evaluations in low- and middle-income countries (LMICs). The International Decision Support Group (iDSI) is a network of health, policy and economic experts. It builds on the approaches of the National Institute for Health and Care Excellence (NICE) in the UK, the Health Intervention and Technology Assessment Program (HITAP) in Thailand and the World Health Organization. iDSI…
Costing Methods | Health Outcomes | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Health/Medicine | Global -
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Technology Assessment | Costing Methods | Priority Setting/Ethics | Evidence Synthesis | Cost-Effectiveness Analysis | Health/Medicine | North America -
GuidelinesPublication 2016Estimating Health-State Utility for Economic Models: ISPOR Task Force Report
Cost-utility models are increasingly used in many countries to establish whether the cost of a …
Cost-utility models are increasingly used in many countries to establish whether the cost of a new intervention can be justified in terms of health benefits. Health-state utility (HSU) estimates (the preference for a given state of health on a cardinal scale where 0 represents dead and 1 represents full health) are typically among the most important and uncertain data inputs in cost-utility models. Clinical trials represent an important opportunity for the collection of health-utility data.…
Technology Assessment | Health Outcomes | Preferences/Values | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Science/Technology | North America | Europe -
GuidelinesPublication 2013Economic Analyses to Support Decisions about HPV Vaccination in Low- and Middle-Income Countries: Consensus Report and Guide
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability …
Low- and middle-income countries need to consider economic issues such as cost-effectiveness, affordability and sustainability before introducing a program for human papillomavirus (HPV) vaccination. However, many such countries lack the technical capacity and data to conduct their own analyses. This report describes the consensus of an expert group convened by the World Health Organization, prioritizing key issues to be addressed when considering economic analyses to support HPV vaccine introduction in these countries. The expert group…
Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
GuidelinesPublication 2012Model Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM Modeling Task Force-6
This paper discusses methods for the reporting of uncertainty, both in terms of deterministic sensitivity …
This paper discusses methods for the reporting of uncertainty, both in terms of deterministic sensitivity analysis techniques and probabilistic methods. Stochastic (first-order) uncertainty is distinguished from both parameter (second-order) uncertainty and from heterogeneity, with structural uncertainty relating to the model itself forming another level of uncertainty. The article describes the process of estimating model inputs, whether these are point estimates or distributions. It also explores the link between parameter uncertainty, decision uncertainty, and value-of-information analysis.…
Calibration/Validation | Value of Information | Mathematical Models | Health/Medicine -
ToolWeb Portal 2023CDC Resource Portal: Diagnostic Tests for SARS-CoV-2
The Centers for Disease Control and Prevention (CDC) provides a broad range of resources about …
The Centers for Disease Control and Prevention (CDC) provides a broad range of resources about diagnostic tests for SARS-CoV-2 aimed at the general public, health professionals and laboratory personnel. The overviews and guidelines for health professionals provide comprehensive information about the current available diagnostics, their strengths and limitations, their performance characteristics and guidelines for their use and interpretation. Selected topics included are provided below. Overview of Testing for SARS-CoV-2, the Virus That Causes COVID-19. Interim…
Test Performance | Infectious Diseases | Clinical Care | Health/Medicine | Science/Technology | North America